QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 satsuma-pharmaceuticals-and-2-other-penny-stocks-insiders-are-aggressively-buying

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidenc...

 satsuma-pharmaceuticals-announces-fda-acceptance-of-505b2-nda-for-sts101-a-novel-and-investigational-dihydroergotamine-nasal-powder-product-for-the-acute-treatment-of-migraine

January 2024 PDUFA date expected If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-co...

 hc-wainwright--co-downgrades-satsuma-pharma-to-neutral

HC Wainwright & Co. analyst Oren Livnat downgrades Satsuma Pharma (NASDAQ:STSA) from Buy to Neutral.

 crude-oil-down-2-state-street-shares-tumble-after-downbeat-results

U.S. stocks traded slightly lower toward the end of trading. The Dow traded down 0.07% to 33,862.05 while the NASDAQ fell 0.24...

 why-satsuma-pharmaceuticals-shares-are-trading-higher-by-94-here-are-other-stocks-moving-in-mondays-mid-day-session

Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.

 gold-drops-below-2000-charles-schwab-earnings-top-views

U.S. stocks traded mostly flat midway through trading, following the release of economic data. The Dow traded up 0.01% to 33,8...

 why-marpai-shares-are-trading-lower-by-26-here-are-20-stocks-moving-premarket

Gainers CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) jumped 153% to $5.96 in pre-market trading after jumping 243% on Friday.

 reported-on-sunday-april-16-snbl-to-acquire-all-outstanding-shares-of-satsuma-for-upfront-cash-consideration-of-091-per-share-satsuma-stockholders-to-also-receive-non-tradeable-contingent-value-right-of-up-to-577-per-share

Transaction delivers immediate value and liquidity to Satsuma stockholders   SNBL to acquire all outstanding shares of Satsuma...

 mizuho-reiterates-neutral-on-satsuma-pharma-maintains-2-price-target

Mizuho analyst Uy Ear reiterates Satsuma Pharma (NASDAQ:STSA) with a Neutral and maintains $2 price target.

 hc-wainwright--co-reiterates-buy-on-satsuma-pharma-maintains-3-price-target

HC Wainwright & Co. analyst Oren Livnat reiterates Satsuma Pharma (NASDAQ:STSA) with a Buy and maintains $3 price target.

 satsuma-pharmaceuticals-q4-eps-070-misses-036-estimate

Satsuma Pharmaceuticals (NASDAQ:STSA) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimat...

 why-universal-electronics-shares-are-trading-lower-by-30-here-are-other-stocks-moving-in-fridays-mid-day-session

Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology tar...

 despite-trial-failure-satsuma-pharma-says-its-migraine-candidate-has-potential-for-approval

Satsuma Pharmaceuticals Inc (NASDAQ: STSA) provided an update on its STS101 development program and corporate update.

 satsuma-pharmaceuticals-says-analysis-of-results-from-recently-completed-summit-phase-3-efficacy-trial-of-sts101-for-the-acute-treatment-of-migraine-shows-differentiating-robust-sustained-antimigraine-effects-on-clinically-important-secondary-endpoints

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update Further analysis of results from recently-c...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION